Raymond James Sticks to Their Buy Rating for Eupraxia Pharmaceuticals (EPRX)
In a report released today, from Raymond James reiterated a Buy rating on Eupraxia Pharmaceuticals, with a price target of $12.00. The company’s shares opened today at C$8.20.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Eupraxia Pharmaceuticals with a C$14.43 average price target, representing a 75.98% upside. In a report released yesterday, Cantor Fitzgerald also maintained a Buy rating on the stock with a $11.00 price target.
EPRX market cap is currently C$292.9M and has a P/E ratio of -6.79.
Based on the recent corporate insider activity of 7 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of EPRX in relation to earlier this year.
Read More on TSE:EPRX:
Disclaimer & DisclosureReport an Issue
- Closing Bell Movers: Progress Software up 4%, Jefferies slips 1% on earnings
- Eupraxia Pharmaceuticals Closes $80.5 Million Public Offering
- Eupraxia announces ‘positive’ data from highest-dose cohort in RESOLVE trial
- Eupraxia Pharmaceuticals Secures $80.5 Million in Public Offering
- Eupraxia Pharmaceuticals Announces Major Share Offering to Boost Capital
